14 results on '"Romero, Briony Duarte"'
Search Results
2. The effect of monthly vitamin D supplementation on fractures: a tertiary outcome from the population-based, double-blind, randomised, placebo-controlled D-Health trial
- Author
-
Waterhouse, Mary, Ebeling, Peter R, McLeod, Donald S A, English, Dallas, Romero, Briony Duarte, Baxter, Catherine, Armstrong, Bruce K, Hartel, Gunter, Kimlin, Michael, O'Connell, Rachel L, van der Pols, Jolieke C, Venn, Alison J, Webb, Penelope M, Whiteman, David C, and Neale, Rachel E
- Published
- 2023
- Full Text
- View/download PDF
3. Vitamin D supplementation and hospitalization for infection in older adults: A post-hoc analysis of data from the Australian D-Health Trial
- Author
-
Pham, Hai, Waterhouse, Mary, Baxter, Catherine, Romero, Briony Duarte, McLeod, Donald SA., Armstrong, Bruce K., Ebeling, Peter R., English, Dallas R., Hartel, Gunter, O’Connell, Rachel L., van der Pols, Jolieke C., Venn, Alison J., Webb, Penelope M., Whiteman, David C., and Neale, Rachel E.
- Published
- 2023
- Full Text
- View/download PDF
4. The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality
- Author
-
Neale, Rachel E, Baxter, Catherine, Romero, Briony Duarte, McLeod, Donald S A, English, Dallas R, Armstrong, Bruce K, Ebeling, Peter R, Hartel, Gunter, Kimlin, Michael G, O'Connell, Rachel, van der Pols, Jolieke C, Venn, Alison J, Webb, Penelope M, Whiteman, David C, and Waterhouse, Mary
- Published
- 2022
- Full Text
- View/download PDF
5. The effect of vitamin D supplementation on pain: an analysis of data from the D-Health randomised controlled trial.
- Author
-
Rahman, Aninda, Waterhouse, Mary, Baxter, Catherine, Romero, Briony Duarte, McLeod, Donald S. A., Armstrong, Bruce K., Ebeling, Peter R., English, Dallas R., Hartel, Gunter, Kimlin, Michael G., O'Connell, Rachel, van der Pols, Jolieke C., Venn, Alison J., Webb, Penelope M., Whiteman, David C., and Neale, Rachel E.
- Subjects
THERAPEUTIC use of vitamin D ,PAIN ,DIETARY supplements ,TREATMENT effectiveness ,RESEARCH funding ,EVALUATION - Abstract
Observational studies suggest that 25-hydroxy vitamin D (25(OH)D) concentration is inversely associated with pain. However, findings from intervention trials are inconsistent. We assessed the effect of vitamin D supplementation on pain using data from a large, double-blind, population-based, placebo-controlled trial (the D-Health Trial). 21 315 participants (aged 60–84 years) were randomly assigned to a monthly dose of 60 000 IU vitamin D
3 or matching placebo. Pain was measured using the six-item Pain Impact Questionnaire (PIQ-6), administered 1, 2 and 5 years after enrolment. We used regression models (linear for continuous PIQ-6 score and log-binomial for binary categorisations of the score, namely 'some or more pain impact' and 'presence of any bodily pain') to estimate the effect of vitamin D on pain. We included 20 423 participants who completed ≥1 PIQ-6. In blood samples collected from 3943 randomly selected participants (∼800 per year), the mean (sd) 25(OH)D concentrations were 77 (sd 25) and 115 (sd 30) nmol/l in the placebo and vitamin D groups, respectively. Most (76 %) participants were predicted to have 25(OH)D concentration >50 nmol/l at baseline. The mean PIQ-6 was similar in all surveys (∼50·4). The adjusted mean difference in PIQ-6 score (vitamin D cf placebo) was 0·02 (95 % CI (−0·20, 0·25)). The proportion of participants with some or more pain impact and with the presence of bodily pain was also similar between groups (both prevalence ratios 1·01, 95 % CI (0·99, 1·03)). In conclusion, supplementation with 60 000 IU of vitamin D3 /month had negligible effect on bodily pain. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
6. Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial.
- Author
-
Thompson, Bridie, Waterhouse, Mary, English, Dallas R., McLeod, Donald S., Armstrong, Bruce K., Baxter, Catherine, Romero, Briony Duarte, Ebeling, Peter R., Hartel, Gunter, Kimlin, Michael G., Rahman, Sabbir T., van der Pols, Jolieke C., Venn, Alison J., Webb, Penelope M., Whiteman, David C., and Neale, Rachel E.
- Subjects
COGNITION disorders ,CONFIDENCE intervals ,MAJOR adverse cardiovascular events ,SELF-evaluation ,DISEASE incidence ,VITAMIN D ,DIETARY supplements ,RANDOMIZED controlled trials ,PLACEBOS ,TREATMENT effectiveness ,BLIND experiment ,DESCRIPTIVE statistics ,STATISTICAL sampling ,OLD age - Published
- 2023
- Full Text
- View/download PDF
7. Vitamin D supplementation and cognition—Results from analyses of the D‐Health trial.
- Author
-
Pham, Hai, Waterhouse, Mary, Rahman, Sabbir, Baxter, Catherine, Romero, Briony Duarte, McLeod, Donald S.A., Armstrong, Bruce K., Ebeling, Peter R., English, Dallas R., Hartel, Gunter, Kimlin, Michael G., O'Connell, Rachel L., van der Pols, Jolieke C., Venn, Alison J., Webb, Penelope M., Whiteman, David C., Almeida, Osvaldo P., and Neale, Rachel E.
- Subjects
CONFIDENCE intervals ,INTERVIEWING ,REGRESSION analysis ,VITAMIN D ,DIETARY supplements ,PLACEBOS ,INDEPENDENT living ,RESEARCH funding ,DESCRIPTIVE statistics ,COGNITIVE testing ,STATISTICAL sampling ,LOGISTIC regression analysis ,ODDS ratio ,SECONDARY analysis ,LONGITUDINAL method - Abstract
Background: Observational studies have consistently found a link between low serum 25‐hydroxyvitamin D concentration and higher risk of cognitive impairment. Results from randomized controlled trials have been mixed, and few have been conducted in the general population. Methods: We recruited 21,315 community‐dwelling Australians aged between 60 and 84 years to participate in the D‐Health Trial, a randomized, double‐blind, placebo‐controlled trial. The intervention was monthly oral doses of 60,000 international units of vitamin D or placebo for 5 years. We assessed cognitive function in a randomly sampled group of participants aged ≥70 years using the Telephone Interview for Cognitive Status (TICS) at 2 and 5 years after randomization. The primary outcome for this analysis was TICS score; the secondary outcome was the proportion of people who had cognitive impairment (defined as TICS score ≤25). We analyzed data using mixed models (linear and logistic). Results: We interviewed 3887 participants at year 2 and 3614 participants at year 5. The mean TICS score at these time points was 32.3 and 32.2, respectively. Vitamin D supplementation did not affect cognitive function as measured by TICS score (mean difference between vitamin D and placebo groups 0.04; 95% CI −0.14 to 0.23), or alter risk of cognitive impairment (odds ratio 1.00; 95% CI 0.75 to 1.33). Conclusions: Monthly bolus doses of vitamin D supplementation neither enhanced nor hindered cognitive function among older adults. Population‐wide vitamin D supplementation of older adults that are largely vitamin D replete is unlikely to substantially benefit cognition. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Effect of vitamin D supplementation on depression in older Australian adults.
- Author
-
Rahman, Sabbir T., Waterhouse, Mary, Romero, Briony Duarte, Baxter, Catherine, English, Dallas R., Almeida, Osvaldo P., Berk, Michael, Ebeling, Peter R., Armstrong, Bruce K., McLeod, Donald S. A., Hartel, Gunter, O'Connell, Rachel L., Pham, Hai, Scott, James G., van der Pols, Jolieke C., Venn, Alison J., Webb, Penelope M., Whiteman, David C., and Neale, Rachel E.
- Abstract
Objectives: To investigate whether vitamin D supplementation reduces depressive symptoms and incidence of antidepressant use.Methods: We used data from the D-Health Trial (N = 21,315), a randomized double-blind placebo-controlled trial of monthly vitamin D3 for the prevention of all-cause mortality. Participants were Australians aged 60-84 years. Participants completed the Patient Health Questionnaire (PHQ-9) at 1, 2 and 5 years after randomization to measure depressive symptoms; national prescribing records were used to capture antidepressant use. We used mixed models and survival models.Results: Analyses of PHQ-9 scores included 20,487 participants (mean age 69·3 years, 46% women); the mean difference (MD) in PHQ-9 score (vitamin D vs. placebo) was 0·02 (95% CI -0·06, 0·11). There was negligible difference in the prevalence of clinically relevant depression (PHQ-9 score ≥10) (odds ratio 0·99; 95% CI 0·90, 1·08). We included 16,670 participants in the analyses of incident antidepressant use (mean age 69·4 years, 43% women). Incidence of antidepressant use was similar between the groups (hazard ratio [HR] 1·04; 95% CI 0·96, 1·12). In subgroup analyses, vitamin D improved PHQ-9 scores in those taking antidepressants at baseline (MD -0·25; 95% CI -0·49, -0·01; p-interaction = 0·02). It decreased risk of antidepressant use in participants with predicted 25(OH)D concentration <50 nmol/L (HR 0·88; 95% CI 0·75, 1·02; p-interaction = 0·01) and increased risk in those with predicted 25(OH)D ≥ 50 nmol/L (HR 1·10; 95% CI 1·01, 1·20).Conclusion: Monthly supplementation with high-dose vitamin D3 was not of benefit for measures of depression overall, but there was some evidence of benefit in subgroup analyses.Clinical Trial Registration: The trial is registered on the Australian New Zealand Clinical Trials Registry: ACTRN12613000743763. https://www.anzctr.org.au/. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
9. The effect of vitamin D supplementation on the gut microbiome in older Australians – Results from analyses of the D-Health Trial.
- Author
-
Pham, Hai, Waterhouse, Mary, Rahman, Sabbir, Baxter, Catherine, Romero, Briony Duarte, McLeod, Donald S. A., Ebeling, Peter R., English, Dallas R., Hartel, Gunter, O’Connell, Rachel L., van der Pols, Jolieke C., Venn, Alison J., Webb, Penelope M., Whiteman, David C., Huygens, Flavia, and Neale, Rachel E.
- Published
- 2023
- Full Text
- View/download PDF
10. The effect of vitamin D supplementation on risk of keratinocyte cancer: an exploratory analysis of the D‐Health randomized controlled trial.
- Author
-
Ali, Sitwat, Pham, Hai, Waterhouse, Mary, Baxter, Catherine, Romero, Briony Duarte, McLeod, Donald S.A., Armstrong, Bruce K., Ebeling, Peter R., English, Dallas R., Hartel, Gunter, van der Pols, Jolieke C., Venn, Alison J., Webb, Penelope M., Whiteman, David C., and Neale, Rachel E.
- Subjects
VITAMIN D ,DIETARY supplements ,SKIN cancer ,COLD therapy ,CURETTAGE ,DISEASE risk factors ,RANDOMIZED controlled trials ,OLDER people - Abstract
Summary: Background: Vitamin D may play a role in prevention of keratinocyte cancer (KC), but observational studies examining the association between serum 25‐hydroxy vitamin D concentration and KC are largely uninformative because sun exposure causes both KC and vitamin D production. There is scant evidence from clinical trials of supplementary vitamin D. Objectives: To examine the effect of vitamin D supplementation on the risk of developing KC. Methods: We used data from the D‐Health Trial, a randomized placebo‐controlled trial of vitamin D supplementation (60 000 international units monthly for 5 years) among Australians aged ≥60 years. KC outcomes were captured through linkage to a national administrative dataset for those who consented (N = 20 334; 95%). We used negative binomial regression to analyse the incidence of KC excisions and the incidence of actinic lesions treated using cryotherapy or serial curettage, and flexible parametric survival models for analysis of time to first KC excision. Results: Randomization to vitamin D supplementation did not reduce the incidence of KC lesions treated by excision [incidence rate ratio (IRR) 1·04; 95% confidence interval (CI) 0·98–1·11], the incidence of actinic lesions treated using other methods (IRR 1·01; 95% CI 0·95–1·08) or time to first histologically confirmed KC excision (hazard ratio 1·02; 95% CI 0·97–1·08). However, in subgroup analysis vitamin D increased the incidence of KC excisions in adults aged ≥ 70 years (IRR 1·13, 95% CI 1·04–1·23; P‐value for interaction = 0·01). Conclusions: Vitamin D supplementation did not reduce the incidence of KC or other actinic lesions. What is already known about this topic?Laboratory studies have suggested possible protective effects of vitamin D on skin cancer.Observational studies investigating the association between vitamin D and risk of keratinocyte cancer are largely uninformative as ultraviolet radiation both causes skin cancer and is the primary source of vitamin D.The evidence from randomized controlled trials of vitamin D is limited and inconclusive. What does this study add?This population‐based, randomized controlled trial suggests that supplementing older adults with a high monthly dose of vitamin D for 5 years does not affect the incidence of keratinocyte cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Vitamin D Supplementation and Antibiotic Use in Older Australian Adults: An Analysis of Data From the D-Health Trial.
- Author
-
Pham, Hai, Waterhouse, Mary, Baxter, Catherine, Romero, Briony Duarte, McLeod, Donald S A, Armstrong, Bruce K, Ebeling, Peter R, English, Dallas R, Hartel, Gunter, Kimlin, Michael G, O'Connell, Rachel L, Pols, Jolieke C van der, Venn, Alison J, Webb, Penelope M, Whiteman, David C, Neale, Rachel E, Duarte Romero, Briony, and van der Pols, Jolieke C
- Subjects
DIETARY supplements ,VITAMIN D ,AUSTRALIANS ,OLDER people ,CLINICAL trial registries ,ANTIBIOTICS ,VITAMIN therapy ,THERAPEUTIC use of vitamin D ,RESEARCH ,RESEARCH methodology ,CHOLECALCIFEROL ,EVALUATION research ,COMPARATIVE studies ,RANDOMIZED controlled trials ,RESEARCH funding - Abstract
Background: Vitamin D supplementation may reduce the risk or severity of infection, but this has been investigated in few large population-based trials. We analyzed data from the D-Health Trial, using prescription of antibiotics as a surrogate for infection.Methods: The D-Health Trial is a randomized, double-blind, placebo-controlled trial in which 21 315 Australians aged 60-84 years were randomized to 60 000 IU of supplementary vitamin D3 or placebo monthly for 5 years. For this analysis, the primary outcome was the number of antibiotic prescription episodes; secondary outcomes were total number of prescriptions, repeat prescription episodes, and antibiotics for urinary tract infection. We estimated incidence rate ratios (IRRs) using negative binomial regression, and odds ratios using logistic regression.Results: Vitamin D supplementation slightly reduced the number of prescription episodes (IRR, 0.98; 95% confidence interval [CI], .95-1.01), total prescriptions (IRR, 0.97; 95% CI, .93-1.00), and repeat prescription episodes (IRR, 0.96; 95% CI, .93-1.00). There was stronger evidence of benefit in people predicted to have insufficient vitamin D at baseline (prescription episodes IRR, 0.93; 95% CI, .87-.99).Conclusions: Vitamin D may reduce the number of antibiotic prescriptions, particularly in people with low vitamin D status. This supports the hypothesis that vitamin D has a clinically relevant effect on the immune system.Clinical Trials Registration: Australian New Zealand Clinical Trials Registry: ACTRN12613000743763. https://www.anzctr.org.au/. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
12. Methodological considerations in D-health cancer mortality results – Authors' reply
- Author
-
Neale, Rachel E, Romero, Briony Duarte, McLeod, Donald S A, English, Dallas R, Hartel, Gunter, van der Pols, Jolieke C, Venn, Alison J, Webb, Penelope M, Whiteman, David C, and Waterhouse, Mary
- Published
- 2022
- Full Text
- View/download PDF
13. Association of Sun Exposure, Skin Colour and Body Mass Index with Vitamin D Status in Individuals Who Are Morbidly Obese.
- Author
-
Dix, Clare F., Bauer, Judith D., Wright, Olivia R. L., Martin, Ian, Rochester, Sharon, Romero, Briony Duarte, and Prins, Johannes B.
- Abstract
Vitamin D deficiency is a common issue, particularly in obese populations, and is tested by assessing serum 25(OH)D concentrations. This study aimed to identify factors that contribute to the vitamin D status in fifty morbidly obese individuals recruited prior to bariatric surgery. Data collected included serum 25(OH)D concentrations, dietary and supplement intake of vitamin D, sun exposure measures, skin colour via spectrophotometry, and genotype analysis of several single nucleotide polymorphisms in the vitamin D metabolism pathway. Results showed a significant correlation between serum 25(OH)D concentrations and age, and serum 25(OH)D and ITAC score (natural skin colour). Natural skin colour accounted for 13.5% of variation in serum 25(OH)D, with every 10° increase in ITAC score (i.e., lighter skin) leading to a 9 nmol/L decrease in serum 25(OH)D. Multiple linear regression using age, ITAC score, and average UV index in the three months prior to testing, significantly predicted serum 25(OH)D concentrations (R² = 29.7%). Single nucleotide polymorphisms for all vitamin D genes tested, showed lower serum 25(OH)D for those with the rare genotype compared to the common genotype; this was most pronounced for fok1 and rs4588, where those with the rare genotype were insufficient (<50 nmol/L), and those with the common genotype were sufficient (≥50 nmol/L). Assessing vitamin D status in individuals with morbid obesity requires testing of 25(OH)D, but potential risk factors for this population include natural skin colour and age. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. Vitamin D Supplementation and the Incidence of Cataract Surgery in Older Australian Adults.
- Author
-
Rahman, Sabbir T., Waterhouse, Mary, Romero, Briony Duarte, Baxter, Catherine, English, Dallas, Mackey, David A., Ebeling, Peter R., Armstrong, Bruce K., McLeod, Donald S.A., Hartel, Gunter, O'Connell, Rachel L., van der Pols, Jolieke C., Venn, Alison J., Webb, Penelope M., Whiteman, David C., and Neale, Rachel E.
- Subjects
- *
VITAMIN D , *DIETARY supplements , *CATARACT surgery , *CHOLECALCIFEROL , *OLDER people - Abstract
Observational studies suggest that higher serum 25-hydroxy vitamin D (25(OH)D) concentration may be associated with lower risk of cataract. However, no randomized controlled trials have assessed the effect of vitamin D supplementation on the incidence of cataract. We aimed to assess whether vitamin D supplementation reduces the incidence of cataract surgery. We conducted an ancillary study of the D-Health Trial, a randomized, double-masked, placebo-controlled trial of monthly vitamin D conducted from 2014 through 2020 within the Australian general population. We invited 421 207 men and women 60 to 84 years of age to participate; including an additional 1896 volunteers, 40 824 expressed interest. Those with hypercalcemia, hyperparathyroidism, kidney stones, osteomalacia, or sarcoidosis or those who were taking more than 500 international units (IU) supplemental vitamin D per day were excluded. A total of 21 315 were randomized, and 1390 participants did not fulfil the eligibility criteria for this analysis (linked data available, no cataract within first 6 months), leaving 19 925 included. The median follow-up was 5 years. Participants took 60 000 IU of vitamin D 3 (n = 10 662) or placebo (n = 10 653) orally once per month for a maximum of 5 years. The primary outcome for this analysis was the first surgical treatment for cataract, ascertained through linkage to universal health insurance records and hospital data. Among 19 925 participants eligible for this analysis (mean age, 69.3 years; 46% women) 3668 participants (18.4%) underwent cataract surgery during follow-up (vitamin D: n = 1841 [18.5%]; placebo: n = 1827 [18.3%]). The incidence of cataract surgery was similar between the two groups (incidence rate, 41.6 and 41.1 per 1000 person-years in the vitamin D and placebo groups, respectively; hazard ratio, 1.02; 95% confidence interval, 0.95–1.09). In prespecified subgroup analyses, the effect of vitamin D supplementation on the incidence of cataract surgery was not modified by age, sex, body mass index, predicted serum 25(OH)D concentration, or ambient ultraviolet radiation. Routinely supplementing older adults who live in an area with a low prevalence of vitamin D deficiency with high-dose vitamin D is unlikely to reduce the need for cataract surgery. Proprietary or commercial disclosure may be found after the references. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.